Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.

ABSTRACT:

Background

Many patients with classical Hodgkin lymphoma show increased programmed death-1 ligand expression in Reed-Sternberg cells. We report the final results of a phase II study of nivolumab, an anti-programmed death-1 monoclonal antibody, in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.

Methods

Japanese patients with previously treated classical Hodgkin lymphoma (aged ≥ 20 years) were administered nivolumab (3 mg/kg on Day 1 of 14-day cycles) until progressive disease, an unacceptable adverse event, or another clinically relevant reason. Treatment could continue beyond progressive disease at the investigator's discretion in selected patients.

Results

Seventeen patients (median age: 63.0 years) were enrolled. The median follow-up was 38

SUBMITTER: Maruyama D 

PROVIDER: S-EPMC7579338 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature